drugset

drugset / Trial / NCT00771823

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

NCT00771823 ↗

Phase 1 Completed 16 enrolled St Stephens Aids Trust

RandomizedCrossoverDouble-blindTreatment

Summary

A placebo controlled study of the impact on insulin sensitivity and lipid profile of maraviroc 300 mg twice daily in HIV negative male volunteers.

Timeline

Start: 2008-05
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Maraviroc	Other / unclassified	300 mg	—

Indications